Caloric Restriction Mimetics
Overview <table class="infobox infobox-therapeutic">
...
Caloric Restriction Mimetics
Overview <table class="infobox infobox-therapeutic">
Caloric restriction mimetics (CRMs) are compounds that reproduce the beneficial effects of caloric restriction (CR) without requiring reduced food intake. CR extends lifespan and improves healthspan across species, with robust evidence in rodents and emerging data in primates and humans. CRMs target key longevity pathways including sirtuins, [mTOR](/mechanisms/mtor-signaling-pathway), AMPK, and insulin/IGF-1 signaling, all of which are implicated in neurodegenerative disease pathogenesis. [@johnson2009]
Mechanism of Action
Caloric Restriction Biology Caloric restriction (20-40% reduction in caloric intake without malnutrition) triggers adaptive cellular responses: [@madeo2014]
Metabolic Shift : Increased ketogenesis and fatty acid oxidationmTOR Inhibition : Reduced protein synthesis and enhanced [autophagy](/entities/autophagy)Sirtuin Activation : NAD+-dependent deacetylases regulate stress resistanceAMPK Activation : Energy sensor activates catabolic pathwaysReduced IGF-1 : Decreased insulin-like growth factor signalingHow CRMs Mimic These Effects
Key Caloric Restriction Mimetics
Rapamycin (Sirolimus)
Class : mTOR inhibitorDose : 1-10 mg/day (various protocols)Status : FDA-approved for transplant rejection and tuberous sclerosisClinical Trials : Multiple for AD, PD, and agingResveratrol
Class : SIRT1 activatorDose : 250-1000 mg/dayStatus : Clinical trials ongoingEvidence : Mixed; some cognitive benefits in pilot studiesClass : AMPK activatorDose : 500-2000 mg/dayStatus : FDA-approved for type 2 diabetesClinical Trials : Multiple neurodegenerative disease trialsSpermidine
Class : Autophagy inducerDose : 1-6 mg/dayStatus : Dietary supplement; clinical trialsEvidence : Promotes autophagy; human cognitive trials ongoingUrolithin A
Class : Mitophagy inducerDose : 500-1000 mg/dayStatus : Clinical trials; approved as dietary supplementEvidence : Improves mitochondrial function in humansClinical Evidence
Alzheimer's Disease
Parkinson's Disease
Aging and Healthspan
CALERIE Trials : Showed metabolic benefits of CR in humansTARGET Studies : Metformin effects on aging biomarkersSENS Research : CRMs as longevity interventionsComparative Efficacy
Combination Approaches CRMs may show synergistic effects:
Rapamycin + Metformin : Dual mTOR/AMPK targetingSpermidine + Resveratrol : Autophagy + sirtuin activationUrolithin A + Exercise : Enhanced mitophagyCRM + Ketogenic Diet : Complementary metabolic pathways
Safety and Considerations
Common Side Effects
Rapamycin : Hyperlipidemia, mouth sores, immunosuppressionMetformin : GI upset (minimized with extended-release)Resveratrol : Generally well-toleratedSpermidine/Urolithin : Minimal reported effectsContraindications
Immunosuppression (rapamycin)
Renal impairment (metformin)
Pregnancy/breastfeeding (most CRMs)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Metabolic Therapy](/therapeutics/metabolic-therapy-neurodegeneration)
[Mitochondrial Therapeutics](/therapeutics/mitochondrial-therapeutics)
[mTOR Pathway](/mechanisms/mtor-pathway)mechanisms/mtor-neurodegeneration)
[Autophagy in Neurodegeneration](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy-lysosomal-pathway)
External Links
[PubMed: Caloric Restriction Mimetics](https://pubmed.ncbi.nlm.nih.gov/?term=caloric+restriction+mimetic+neurodegeneration)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[SENS Research Foundation](https://www.sens.org/)
[Lifespan.io](https://lifespan.io/)
References
[Johnson et al., Rapamycin extends lifespan in mice (2009) (2009)](https://doi.org/10.1038/nature08221)
[Madeo et al., Spermidine extends lifespan (2014) (2014)](https://doi.org/10.1126/science.1241940)
[Howitz et al., Resveratrol as sirtuin activator (2003) (2003)](https://doi.org/10.1038/nature01960)
[Ryu et al., Natural mitophagy inducer urolithin A (2016) (2016)](https://doi.org/10.1016/j.redox.2016.10.005)
[Barzilai et al., Metformin as anti-aging therapy (2012) (2012)](https://doi.org/10.1111/j.1474-9726.2012.00824.x)
Unknown, NCT03053596 Clinical Trial (n.d.)
Unknown, NCT04482755 Clinical Trial (n.d.)
[Redman et al., CALERIE trial outcomes (2018) (2018)](https://doi.org/10.1038/s41586-018-0757-z)
[Smith et al., CRM combinations for neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.tips.2020.06.010)
[Vinciguerra et al., mTOR in neurodegeneration (2022) (2022)](https://doi.org/10.1007/s00018-022-04187-4)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics](/hypothesis/h-513a633f) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ANXA1
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
Related Analyses:
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Mechanistic role of APOE in neurodegeneration](/analysis/SDA-2026-04-01-gap-auto-fd6b1635d9) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
Show full description